BioScale, Inc.

At BioScale, we develop, manufacture and promote a sophisticated protein measurement technology to accelerate drug discovery, development and production of biological and pharmaceutical products.  The simplicity, power and speed of our innovative technology enables our customers to achieve major advancements in protein research that were not previously attainable by allowing the ultra-sensitive detection of  proteins in multiple types of complex biological samples.  Key applications are available for bioprocess and biologics-oriented scientists  that uniquely addresses impurity testing and product titer needs with highly reproducible detection and quantitation in complex biological mixtures.  Used across the drug development spectrum including early discovery and development, preclinical development and clinical trials, typical applications include biomarker discovery, biomarker monitoring, pharmacokinetics, pharmacodynamics, toxicokinetics and protein expression.

BioScale was founded in 2002 by CEO Mark Lundstrom and three interdisciplinary MIT professors.  Since then the Company has assembled development, engineering, manufacturing and an industry-seasoned commercial team to globally launch our AMMP assay technology and ViBE platform into the pharmaceutical, biotech, life science, and bioprocess markets. We are also pursuing partnering for diagnostic and specialty applications.  The Company's  30,000 sq. ft. global headquarters and manufacturing site are located in Lexington, Massachusetts.